Evidence map›Paper›PMID 42516270›Full record

ArticleFrontiers in bioinformatics2026

Comparative evaluation of reference-free transcriptomic deconvolution highlights the importance of biological validation in astrocytes across Alzheimer's disease.

Laura Rodríguez-Millan, Andrea Angarita-Rodríguez, Viviana Vargas-López, Andrés Pinzón, Estefania Tarifeño-Saldivia, Janneth González

Abstract read
In one paragraph

Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura Rodríguez-Millan *Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.
Andrea Angarita-Rodríguez *Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.
Viviana Vargas-LópezDepartamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.
Andrés PinzónLaboratorio de Bioinformática y Biología de Sistemas, Universidad Nacional de Colombia Bogotá, Bogotá, Colombia.
Estefania Tarifeño-SaldiviaDepartment of Biochemistry and Molecular Biology, Faculty of Biological Sciences, University of Concepción, Concepción, Chile.
Janneth GonzálezDepartamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Astrocytes are central regulators of neuronal energy metabolism and redox homeostasis-processes that become progressively disrupted across the Alzheimer's disease (AD) continuum. However, bulk transcriptomic data obscure cell-type-specific signals, and existing reference-free deconvolution methods often prioritize either statistical robustness or quantitative accuracy without fully integrating both dimensions. Methods: Here, we present a comparative framework evaluating two complementary unsupervised approaches, CDSeq and DECODER, to reconstruct astrocyte-associated transcriptomic profiles from human hippocampal samples spanning control, mild cognitive impairment (incipient and moderate), and AD (severe) stages (GSE28146; n = 30). The inferred profiles were functionally contextualized through integration into a genome-scale metabolic model of human astrocytes, enabling the assessment of system-level metabolic alterations associated with disease progression. Results: Our results reveal consistent dysregulation of key astrocytic pathways, including impairment of the astrocyte-neuron lactate shuttle, disruption of glutamine metabolism, and reduced glutathione-mediated an oxidant capacity. Methodological benchmarking showed distinct yet complementary performance profiles: DECODER achieved higher accuracy in reconstructing global expression magnitudes, whereas CDSeq exhibited greater stability and preservation of gene-gene relationships. Crucially, external validation using independent single-nucleus RNA-seq astrocyte data demonstrated that CDSeq-derived profiles achieve moderate but robust concordance with reference signatures (r ≈ 0.43-0.44), substantially exceeding DECODER-derived concordance (r ≈ 0.19-0.23), with higher concordance with astrocyte-associated signatures, alongside preservation of canonical astrocyte markers and enrichment of astrocyte-specific pathways, indicating superior biological coherence. Discussion: Together, these findings demonstrate that technical accuracy does not necessarily translate into biological validity and highlight CDSeq as the method that more reliably captures astrocyte-specific transcriptional programs in this context. While DECODER remains valuable for detecting absolute expression changes, CDSeq provides a more consistent recovery of astrocyte-associated transcriptional patterns. More broadly, our results support the incorporation of biological validation alongside statistical benchmarking when selecting deconvolution methods for downstream systems biology and metabolic modeling applications. This framework establishes a reproducible strategy for evaluating deconvolution methods and their functional consequences, advancing the interpretation of bulk transcriptomic data in neurodegenerative disease.

Indexed as

Alzheimer’s diseaseastrocytesbulk RNA-seqCDSeqcognitive impairmentDECODERtranscriptomic deconvolution

Identifiers

PMID42516270
PMCPMC13402868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.